L Okamoto

1.3k total citations
22 papers, 1.0k citations indexed

About

L Okamoto is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, L Okamoto has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Physiology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in L Okamoto's work include Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). L Okamoto is often cited by papers focused on Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). L Okamoto collaborates with scholars based in United States, United Kingdom and Mexico. L Okamoto's co-authors include W. Brian Saunders, Kenneth A. Lawson, David H. Smith, Carmelina Battista, Trent McLaughlin, Richard H. Stanford, Puneet Mahajan, Rami Ben‐Joseph, Adrianne C. Feldstein and Marsha A. Raebel and has published in prestigious journals such as Gastroenterology, American Journal of Respiratory and Critical Care Medicine and Journal of Allergy and Clinical Immunology.

In The Last Decade

L Okamoto

21 papers receiving 943 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L Okamoto United States 12 575 379 168 143 103 22 1.0k
Christopher M. Blanchette United States 22 503 0.9× 738 1.9× 143 0.9× 155 1.1× 93 0.9× 84 1.7k
Trent McLaughlin United States 17 273 0.5× 231 0.6× 138 0.8× 92 0.6× 181 1.8× 50 994
Kurtis S. Elward United States 16 652 1.1× 507 1.3× 308 1.8× 74 0.5× 67 0.7× 28 1.2k
Charon Gwynn United States 9 998 1.7× 576 1.5× 296 1.8× 151 1.1× 66 0.6× 11 1.8k
Timothy L Frank United Kingdom 15 366 0.6× 317 0.8× 135 0.8× 127 0.9× 90 0.9× 39 834
A Lahdensuo Finland 18 708 1.2× 754 2.0× 158 0.9× 103 0.7× 27 0.3× 39 1.2k
Rebecca Normansell United Kingdom 18 1.1k 1.8× 824 2.2× 200 1.2× 121 0.8× 27 0.3× 27 1.7k
Andrew Stoddart United Kingdom 14 225 0.4× 328 0.9× 276 1.6× 147 1.0× 42 0.4× 37 1.1k
Tursynbek Nurmagambetov United States 10 833 1.4× 504 1.3× 335 2.0× 91 0.6× 129 1.3× 17 1.4k
Prakash Navaratnam United States 15 348 0.6× 258 0.7× 121 0.7× 48 0.3× 85 0.8× 65 736

Countries citing papers authored by L Okamoto

Since Specialization
Citations

This map shows the geographic impact of L Okamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Okamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Okamoto more than expected).

Fields of papers citing papers by L Okamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Okamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Okamoto. The network helps show where L Okamoto may publish in the future.

Co-authorship network of co-authors of L Okamoto

This figure shows the co-authorship network connecting the top 25 collaborators of L Okamoto. A scholar is included among the top collaborators of L Okamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Okamoto. L Okamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Okamoto, L, et al.. (2021). Renaissance in the Nursing Home During the COVID-19 Pandemic: Telemedicine Blooms in a Time of Crisis. Journal of the American Medical Directors Association. 22(3). B16–B16. 2 indexed citations
2.
Boudreau, Denise M., Daniel C. Malone, Marsha A. Raebel, et al.. (2009). Health Care Utilization and Costs by Metabolic Syndrome Risk Factors. Metabolic Syndrome and Related Disorders. 7(4). 305–314. 166 indexed citations
3.
Malone, Dan, Denise M. Boudreau, Marsha A. Raebel, et al.. (2009). Association of Cardiometabolic Risk Factors and Prevalent Cardiovascular Events. Metabolic Syndrome and Related Disorders. 7(6). 585–594. 9 indexed citations
4.
Beaton, Sarah J., Scott B. Robinson, Ann Von Worley, et al.. (2009). Cardiometabolic Risk and Health Care Utilization and Cost for Hispanic and Non-Hispanic Women. Population Health Management. 12(4). 177–183. 4 indexed citations
5.
Okamoto, L. (2006). Outcomes and Humanistic Issues Related to Treatment of Acute Bronchospasm. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(9P2). 175S–80S. 1 indexed citations
6.
Hollenbeak, Christopher S., Rami Ben‐Joseph, L Okamoto, et al.. (2006). Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited. Value in Health. 10. S4–S11. 6 indexed citations
7.
Jaime, J., Judith A. O’Brien, Christopher S. Hollenbeak, et al.. (2006). Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk Profiles. Value in Health. 10. S12–S20. 24 indexed citations
8.
9.
McLaughlin, Trent P., et al.. (2001). Concomitant use of proton pump inhibitors and metabolically competing drugs, and the risk of drug-drug interaction induced adverse events. Gastroenterology. 120(5). A402–A402. 2 indexed citations
10.
Stanford, Richard H., L Okamoto, & Trent McLaughlin. (2000). Rates of hospitalization for asthma by insurance status.. PubMed. 2(1). E5–E5. 3 indexed citations
11.
Cox, Felicia, Krishnan Ramaswamy, L Okamoto, & Trent McLaughlin. (2000). PRS8: TREATMENT AND ASSOCIATED COSTS OF NEWLY DIAGNOSED COPD PATIENTS IN A MANAGED CARE POPULATION. Value in Health. 3(5). 329–330. 1 indexed citations
12.
Okamoto, L, et al.. (2000). Cost associated with the treatment of influenza in a managed care setting.. PubMed. 2(4). E34–E34. 12 indexed citations
13.
Cox, Fred M., et al.. (2000). Cost of treating influenza in emergency department and hospital settings.. PubMed. 6(2). 205–14. 25 indexed citations
14.
Stanford, Richard H., Trent McLaughlin, & L Okamoto. (1999). The Cost of Asthma in the Emergency Department and Hospital. American Journal of Respiratory and Critical Care Medicine. 160(1). 211–215. 108 indexed citations
15.
Mahajan, Puneet, David S. Pearlman, & L Okamoto. (1998). The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents. Journal of Allergy and Clinical Immunology. 102(1). 19–23. 37 indexed citations
16.
Smith, David H., et al.. (1997). A National Estimate of the Economic Costs of Asthma. American Journal of Respiratory and Critical Care Medicine. 156(3). 787–793. 462 indexed citations
17.
Mahajan, Puneet & L Okamoto. (1997). Patient satisfaction with the Diskhaler® and the Diskus® inhaler, a new multidose powder delivery system for the treatment of asthma. Clinical Therapeutics. 19(5). 1126–1134. 23 indexed citations
18.
Mahajan, Puneet, et al.. (1997). Impact of Fluticasone Propionate Powder on Health-Related Quality of Life in Patients with Moderate Asthma. Journal of Asthma. 34(3). 227–234. 44 indexed citations
19.
Nielsen, Kirsten Vang, L Okamoto, & Tushar Shah. (1997). Importance of Selected Inhaler Characteristics and Acceptance of a New Breath-Actuated Powder Inhalation Device. Journal of Asthma. 34(3). 249–253. 19 indexed citations
20.
Okamoto, L, Michael Noonan, Bennett P. deBoisblanc, & Donald J. Kellerman. (1996). Fluticasone Propionate Improves Quality of Life in Patients with Asthma Requiring Oral Corticosteroids. Annals of Allergy Asthma & Immunology. 76(5). 455–461. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher M. Blanchette Breakdown of academic impact, for papers by Trent McLaughlin Breakdown of academic impact, for papers by Kurtis S. Elward Breakdown of academic impact, for papers by Charon Gwynn Breakdown of academic impact, for papers by Timothy L Frank Breakdown of academic impact, for papers by A Lahdensuo Breakdown of academic impact, for papers by Rebecca Normansell Breakdown of academic impact, for papers by Andrew Stoddart Breakdown of academic impact, for papers by Tursynbek Nurmagambetov Breakdown of academic impact, for papers by Prakash Navaratnam
Rankless by CCL
2026